KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
Medical - Instruments & Supplies
Market Cap$1.26B
5Y Perf.-13.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
KMTS vs LIVN
Revenue, margins, valuation, and 5-year total return — side by side.
LIVN
LivaNova PLC
Medical - Devices
Market Cap$3.88B
5Y Perf.+80.6%
KMTS vs LIVN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | KMTS | LIVN |
|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $1.26B | $3.88B |
| Revenue (TTM) | $84M | $1.43B |
| Net Income (TTM) | $-145M | $107M |
| Gross Margin | 48.8% | 67.5% |
| Operating Margin | -171.5% | 13.4% |
| Forward P/E | — | 16.8x |
| Total Debt | $44M | $473M |
| Cash & Equiv. | $238M | $636M |
KMTS vs LIVN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KMTS
LIVN
| Stock | Mar 25 | May 26 | Return |
|---|---|---|---|
| KESTRA MEDICAL TECH… (KMTS) | 100 | 86.4 | -13.6% |
| LivaNova PLC (LIVN) | 100 | 180.6 | +80.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KMTS vs LIVN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: LIVN leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. KESTRA MEDICAL TECHNOLOGIES, LTD. is the stronger pick specifically for growth and revenue expansion and dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
The Growth Play
KMTS is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- Rev growth 115.1%, EPS growth -151.5%
- Lower volatility, beta 1.87, Low D/E 21.6%, current ratio 6.72x
- 115.1% revenue growth vs LIVN's 10.7%
Best for: growth exposure and sleep-well-at-night
LIVN
LivaNova PLC
The Income Pick
LIVN carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.29
- 46.2% 10Y total return vs KMTS's -1.5%
- Beta 1.29, current ratio 1.36x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | KMTS | 115.1% revenue growth vs LIVN's 10.7% |
| Quality / Margins | LIVN | 7.5% margin vs KMTS's -173.0% |
| Stability / Safety | LIVN | Beta 1.29 vs KMTS's 1.87 |
| Dividends | KMTS | 0.2% yield; 5-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | LIVN | +63.0% vs KMTS's -1.5% |
| Efficiency (ROA) | LIVN | 4.2% ROA vs KMTS's -48.8%, ROIC 11.5% vs -6.6% |
KMTS vs LIVN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
KMTS vs LIVN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLLIVNLAGGINGKMTS
KMTSKESTRA MEDICAL TECHNO…
0leads
LIVNLivaNova PLC
5leads
6 Total Categories
CATEGORYLEADERvs KMTSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
LIVN5/6
Valuation MetricsMultiples, price ratios, and targets
LIVN3/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
LIVN5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
LIVN5/6
Risk & VolatilityBeta, volatility, and downside exposure
LIVN2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
LIVN leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
LIVN is the larger business by revenue, generating $1.4B annually — 17.1x KMTS's $84M. LIVN is the more profitable business, keeping 7.5% of every revenue dollar as net income compared to KMTS's -173.0%. On growth, KMTS holds the edge at +62.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | KMTSKESTRA MEDICAL TE… | LIVNLivaNova PLC |
|---|---|---|
| RevenueTrailing 12 months | $84M | $1.4B |
| EBITDAEarnings before interest/tax | -$142M | $220M |
| Net IncomeAfter-tax profit | -$145M | $107M |
| Free Cash FlowCash after capex | -$120M | $161M |
| Gross MarginGross profit ÷ Revenue | +48.8% | +67.5% |
| Operating MarginEBIT ÷ Revenue | -171.5% | +13.4% |
| Net MarginNet income ÷ Revenue | -173.0% | +7.5% |
| FCF MarginFCF ÷ Revenue | -143.3% | +11.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +62.7% | +14.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -22.0% | +106.7% |
LIVN leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
LIVN leads this category, winning 3 of 3 comparable metrics.
Valuation Metrics
| Metric | KMTSKESTRA MEDICAL TE… | LIVNLivaNova PLC |
|---|---|---|
| Market CapShares × price | $1.3B | $3.9B |
| Enterprise ValueMkt cap + debt − cash | $1.1B | $3.7B |
| Trailing P/EPrice ÷ TTM EPS | -4.19x | -15.94x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 16.84x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 15.40x |
| Price / SalesMarket cap ÷ Revenue | 20.99x | 2.79x |
| Price / BookPrice ÷ Book value/share | 5.19x | 3.22x |
| Price / FCFMarket cap ÷ FCF | — | 22.40x |
LIVN leads this category, winning 3 of 3 comparable metrics.
Profitability & Efficiency
LIVN leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
LIVN delivers a 9.1% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-69 for KMTS. KMTS carries lower financial leverage with a 0.22x debt-to-equity ratio, signaling a more conservative balance sheet compared to LIVN's 0.39x. On the Piotroski fundamental quality scale (0–9), KMTS scores 6/9 vs LIVN's 5/9, reflecting solid financial health.
| Metric | KMTSKESTRA MEDICAL TE… | LIVNLivaNova PLC |
|---|---|---|
| ROE (TTM)Return on equity | -68.8% | +9.1% |
| ROA (TTM)Return on assets | -48.8% | +4.2% |
| ROICReturn on invested capital | -6.6% | +11.5% |
| ROCEReturn on capital employed | -78.6% | +10.2% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 5 |
| Debt / EquityFinancial leverage | 0.22x | 0.39x |
| Net DebtTotal debt minus cash | -$193M | -$162M |
| Cash & Equiv.Liquid assets | $238M | $636M |
| Total DebtShort + long-term debt | $44M | $473M |
| Interest CoverageEBIT ÷ Interest expense | -13.93x | 3.98x |
LIVN leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
LIVN leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KMTS five years ago would be worth $9,853 today (with dividends reinvested), compared to $8,546 for LIVN. Over the past 12 months, LIVN leads with a +63.0% total return vs KMTS's -1.5%. The 3-year compound annual growth rate (CAGR) favors LIVN at 14.6% vs KMTS's -0.5% — a key indicator of consistent wealth creation.
| Metric | KMTSKESTRA MEDICAL TE… | LIVNLivaNova PLC |
|---|---|---|
| YTD ReturnYear-to-date | -11.8% | +17.0% |
| 1-Year ReturnPast 12 months | -1.5% | +63.0% |
| 3-Year ReturnCumulative with dividends | -1.5% | +50.5% |
| 5-Year ReturnCumulative with dividends | -1.5% | -14.5% |
| 10-Year ReturnCumulative with dividends | -1.5% | +46.2% |
| CAGR (3Y)Annualised 3-year return | -0.5% | +14.6% |
LIVN leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
LIVN leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
LIVN is the less volatile stock with a 1.29 beta — it tends to amplify market swings less than KMTS's 1.87 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LIVN currently trades 98.6% from its 52-week high vs KMTS's 71.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KMTSKESTRA MEDICAL TE… | LIVNLivaNova PLC |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.87x | 1.29x |
| 52-Week HighHighest price in past year | $30.00 | $71.92 |
| 52-Week LowLowest price in past year | $13.25 | $39.36 |
| % of 52W HighCurrent price vs 52-week peak | +71.7% | +98.6% |
| RSI (14)Momentum oscillator 0–100 | 48.1 | 57.6 |
| Avg Volume (50D)Average daily shares traded | 357K | 808K |
LIVN leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates KMTS as "Buy" and LIVN as "Buy". Consensus price targets imply 30.1% upside for KMTS (target: $28) vs 7.0% for LIVN (target: $76). KMTS is the only dividend payer here at 0.16% yield — a key consideration for income-focused portfolios.
| Metric | KMTSKESTRA MEDICAL TE… | LIVNLivaNova PLC |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $28.00 | $75.88 |
| # AnalystsCovering analysts | 4 | 14 |
| Dividend YieldAnnual dividend ÷ price | +0.2% | — |
| Dividend StreakConsecutive years of raises | 5 | — |
| Dividend / ShareAnnual DPS | $0.03 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.1% |
Insufficient data to determine a leader in this category.
Key Takeaway
LIVN leads in 5 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics.
Best OverallLivaNova PLC (LIVN)Leads 5 of 6 categories
Loading custom metrics...
KMTS vs LIVN: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is KMTS or LIVN a better buy right now?
For growth investors, KESTRA MEDICAL TECHNOLOGIES, LTD.
(KMTS) is the stronger pick with 115. 1% revenue growth year-over-year, versus 10. 7% for LivaNova PLC (LIVN). Analysts rate KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — KMTS or LIVN?
Over the past 5 years, KESTRA MEDICAL TECHNOLOGIES, LTD.
(KMTS) delivered a total return of -1. 5%, compared to -14. 5% for LivaNova PLC (LIVN). Over 10 years, the gap is even starker: LIVN returned +46. 2% versus KMTS's -1. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — KMTS or LIVN?
By beta (market sensitivity over 5 years), LivaNova PLC (LIVN) is the lower-risk stock at 1.
29β versus KESTRA MEDICAL TECHNOLOGIES, LTD. 's 1. 87β — meaning KMTS is approximately 45% more volatile than LIVN relative to the S&P 500. On balance sheet safety, KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) carries a lower debt/equity ratio of 22% versus 39% for LivaNova PLC — giving it more financial flexibility in a downturn.
04Which is growing faster — KMTS or LIVN?
By revenue growth (latest reported year), KESTRA MEDICAL TECHNOLOGIES, LTD.
(KMTS) is pulling ahead at 115. 1% versus 10. 7% for LivaNova PLC (LIVN). On earnings-per-share growth, the picture is similar: KESTRA MEDICAL TECHNOLOGIES, LTD. grew EPS -151. 5% year-over-year, compared to -483. 6% for LivaNova PLC. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — KMTS or LIVN?
LivaNova PLC (LIVN) is the more profitable company, earning -17.
5% net margin versus -190. 3% for KESTRA MEDICAL TECHNOLOGIES, LTD. — meaning it keeps -17. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LIVN leads at 14. 4% versus -177. 8% for KMTS. At the gross margin level — before operating expenses — LIVN leads at 67. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is KMTS or LIVN more undervalued right now?
Analyst consensus price targets imply the most upside for KMTS: 30.
1% to $28. 00.
07Which pays a better dividend — KMTS or LIVN?
In this comparison, KMTS (0.
2% yield) pays a dividend. LIVN does not pay a meaningful dividend and should not be held primarily for income.
08Is KMTS or LIVN better for a retirement portfolio?
For long-horizon retirement investors, LivaNova PLC (LIVN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
29)). KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) carries a higher beta of 1. 87 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LIVN: +46. 2%, KMTS: -1. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between KMTS and LIVN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: KMTS is a small-cap high-growth stock; LIVN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(KMTS: 62.7% · LIVN: 14.3%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.